Table 3.
Univariate analysis of survival in all patients (n = 25).
| PFS |
OS |
|||
|---|---|---|---|---|
| HR [95%CI] | P value | HR [95%CI] | P value | |
| Age | 0.932 [0.411, 2.113] | 0.867 | 2.089 [0.818, 5.336] | 0.123 |
| >60 years versus ≤60 years | ||||
| Sex | 1.09 [0.448, 2.655] | 0.849 | 0.575 [0.205, 1.61] | 0.292 |
| Female versus male | ||||
| Smoking status | 0.631 [0.255, 1.559] | 0.318 | 2.912 [0.944, 8.978] | 0.063 |
| Ever/current versus never | ||||
| Pre-treatment | 0.192 | 0.598 | ||
| Chemo | ||||
| Chemo+RT | 0.74 [0.23, 2.382] | 0.614 | 0.446 [0.122, 1.629] | 0.222 |
| Chemo+anti-angiogenesis | 0.202 [0.038, 1.069] | 0.060 | 0.549 [0.123, 2.447] | 0.431 |
| Treatment | 0.655 [0.262, 1.633] | 0.364 | 1.984 [0.675, 5.829] | 0.213 |
| IO versus IO plus other treatment | ||||
| Histopathologic type | 1.226 [0.538, 2.794] | 0.628 | 1.412 [0.571, 3.495] | 0.455 |
| Adenocarcinoma versus | ||||
| Squamous carcinoma | ||||
| Lines of chemo | 0.617 [0.136, 2.79] | 0.53 | 0.034 [0, 7.292] | 0.217 |
| 3 versus 2 | ||||
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; Chemo, chemotherapy; RT, radiotherapy; IO, PD1/PD-L1 immunotherapy.